The O.H.I.O. Fund backs T45 Fund-II’s cardiovascular company-building model
Sourced news brief · See the publication date above and original source below.
Private funds advised by The O.H.I.O. Fund have invested in T45 Fund-II, T45 Labs and the Ohio investor announced November 3. Financial terms were not disclosed.
T45 Labs builds cardiovascular-device companies and says the investment will support portfolio development in Cleveland. Its first portfolio company, Advanced NanoTherapies, licenses drug-coated-balloon technology from Cleveland Clinic and manufactures its platform in Ohio. Other named portfolio companies include Mitria Medical, VahatiCor and NuevoSono.
This is an investment in T45 Fund-II, not a disclosed financing round for any one portfolio company and not a published fund-size announcement. Company descriptions of de-risking technologies and moving them toward clinical, regulatory or acquisition milestones do not establish patient outcomes or successful exits.
Browse Ohio startup and venture coverage and the Heartland newsroom.